WO2005108464A1 - 架橋ポリロタキサンを有する材料、並びにそれらの製造方法 - Google Patents
架橋ポリロタキサンを有する材料、並びにそれらの製造方法 Download PDFInfo
- Publication number
- WO2005108464A1 WO2005108464A1 PCT/JP2005/008346 JP2005008346W WO2005108464A1 WO 2005108464 A1 WO2005108464 A1 WO 2005108464A1 JP 2005008346 W JP2005008346 W JP 2005008346W WO 2005108464 A1 WO2005108464 A1 WO 2005108464A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- molecule
- taxane
- cyclodextrin
- crosslinked
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/265—Synthetic macromolecular compounds modified or post-treated polymers
- B01J20/267—Cross-linked polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/007—Polyrotaxanes; Polycatenanes
Definitions
- the present invention relates to a material having a cross-linked polytaxane obtained by cross-linking polytaxanes, and a method for producing the same.
- the present invention relates to a material having a crosslinked polyporous taxane in which an OH group of a cyclic molecule contained in the polyporous taxane has been substituted with a group having an ionic group, and a method for producing the same.
- Polymouth taxanes are pseudo-polyrotaxanes in which the opening of a cyclic molecule (rotator) is skewer-likely enclosed by a linear molecule (axis: axis). At both ends), blocking groups are arranged so as not to release the cyclic molecule.
- cyclodextrin hereinafter, cyclodextrin may be simply abbreviated as “CD”) may be used as a cyclic molecule
- PEG polyethylene glycol
- polytaxanes see, for example, Patent Document 1 have various properties, their studies have been actively conducted in recent years.
- Patent Document 2 discloses a compound having a crosslinked polyporous taxane having properties as a so-called slipping gel or sliding gel or properties as a viscoelastic material.
- Patent Document 2 discloses a cross-linked poly-taxane obtained by cross-linking (bonding) poly-taxanes formed by encapsulating a linear molecule of PEG to a cyclic molecule, a hi-CD molecule, through a chemical bond. Specifically disclosed.
- a material having a crosslinked polyporous taxane is required to have further improved swellability.
- a material having a responsiveness to the electric field, in particular, a fast responsiveness is required.
- Patent Document 1 Japanese Patent No. 2810264.
- Patent Document 2 Japanese Patent No. 3475252. Disclosure of the invention
- an object of the present invention is to solve the above problem.
- a material having a crosslinked polytaxane whose swelling property changes with a change in pH and / or ionic strength is an object of the present invention to provide a material having a crosslinked polytaxane whose swelling property changes with a change in pH and / or ionic strength.
- Another object of the present invention is to provide a material having a crosslinked polyrotaxane having responsiveness to an electric field when the electric field of the environment changes, particularly high-speed response, in addition to or in addition to the above-mentioned object. Is to do.
- the present inventors have conducted intensive studies to achieve the above object, and as a result, by substituting at least a part of the hydroxyl group of the cyclic molecule constituting the polyporous taxane with a group having an ionic group. It has been found that it is possible to control the properties of the cross-linked polytaxane, in particular, the swellability, that is, the solvent absorption properties, the change in swellability (volume) due to pH and / or ion strength, and the change in behavior in an electric field atmosphere.
- the swellability that is, the solvent absorption properties, the change in swellability (volume) due to pH and / or ion strength, and the change in behavior in an electric field atmosphere.
- ⁇ 1> At least a polyporous taxane in which a linear molecule is skewered in the opening of a cyclic molecule in a skewered manner and a blocking group is arranged at both ends of the linear molecule so that the cyclic molecule is not detached.
- Some of the hydroxyl groups are _CO ⁇ X groups (X represents hydrogen (H), alkali metals and other monovalent metals), -SO X groups (X has the same definition as above), -NH groups
- ⁇ ' represents a monovalent halogen ion
- the group having an ionic group is substituted with 10 to 90%, preferably 20 to 80%, more preferably 30 to 70% of all hydroxyl groups of all cyclic molecules. It is better to be done.
- the material may absorb 100,000 g or more, preferably 2000 g or more, more preferably 4000 g or more of a solvent per lg of the absolute dry state of the crosslinked polytaxane.
- the material absorbs a solvent containing water, and the volume of the material changes as the pH and Z or the ionic strength of the solvent changes.
- the material may absorb at least 5 g, preferably at least 10 g, more preferably at least 50 g of solvent per lg of absolute dryness of the crosslinked polyporous taxane at pH2, while at the same time absorb absolutely lg of the solvent at pHIO. It is better to absorb 500 g or more, preferably 100 g or more, more preferably 2000 g or more per solvent.
- the solvent absorbs at least 5 g, preferably at least 10 g, more preferably at least 50 g of the solvent per lg of absolute dry lg of the crosslinked polytaxane having an ionic strength of 10 _1 mol / L, while having a ionic strength of 10 _3 mol / L.
- the solvent should be absorbed in an amount of 200 g or more, preferably 500 g or more, more preferably 100 g or more per lg.
- the material may absorb a solvent containing water, and the material having absorbed the solvent may change its shape and / or volume by an electric field.
- the electric field causes the cationic cyclic molecule to be localized on the negative electrode side, thereby changing the shape and / or volume of the material, for example, bending or ionizing.
- the functional group is anionic, it is preferable that the cyclic molecule having anionic properties be localized on the positive electrode side by an electric field, whereby the shape and Z or volume of the material change, for example, bend.
- the cyclic molecule may be a cyclodextrin molecule.
- cyclic molecule is a cyclodextrin molecule
- the cyclodextrin molecule is a group consisting of monocyclodextrin, ⁇ -cyclodextrin, and ⁇ -cyclodextrin. It is better to choose from.
- the blocking group may be a dinitrophenyl group, a cyclodextrin, an adamantane group, a trityl group, a fluorescein, a pyrene, a substituted benzene (substituent) Examples include, but are not limited to, alkyl, alkyloxy, hydroxy, halogen, cyano, sulfonyl, carboxyl, amino, phenyl, etc.
- Polynuclear aromatics include, but are not limited to, the same as those described above; one or more substituents may be present); and steroids It is better to choose from a group. In addition, it is preferably selected from the group consisting of dinitrophenyl groups, cyclodextrins, adamantane groups, trityl groups, fluoresceins, and pyrenes, more preferably adamantane groups or trityl groups. .
- the cyclic molecule may be ⁇ -cyclodextrin, and the linear molecule may be polyethylene glycol.
- the amount of inclusion of the cyclic molecule to the maximum is determined.
- the cyclic molecular force SO.001 to 0.6, preferably 00.01 to 0.5, more preferably 0.050.05 to 0.4 is included in a skewer-like inclusion in the linear molecule. Good.
- the crosslinking agent may have a molecular weight of less than 2000, preferably less than 1000, more preferably less than 600, and most preferably less than 400. Good.
- the crosslinking agent may be, for example, cyanuric chloride, trimesyl chloride, terephthalone rechloride, epichlorohydrin, dibromobenzene, gnoletrenoleanolaldehyde, or phenylene diisocyanate. Catenate, trilein diisocyanate, divinyl sulfone, 1,1′-carbonyldiimidazole, and alkoxysilane.
- At least two molecules of the polymouth taxane may be formed by crosslinking at least one ⁇ group of at least one cyclic molecule of each polymouth taxane. It is better to be involved.
- the linear molecule may have a molecular weight of at least 10,000, preferably at least 20,000, more preferably at least 350,000.
- a method for preparing a material having a crosslinked polymouth taxane comprising the steps of: 1) mixing a cyclic molecule having a ⁇ ⁇ group with a linear molecule to form a linear molecule at an opening of the cyclic molecule; A pseudo-polyrotaxane preparation step of preparing a pseudo-polyrotaxane to be included in a skewer-like manner; 2) a pseudo-polyrotaxane is prepared by blocking both ends of the pseudo-polyrotaxane with blocking groups so that the cyclic molecule does not detach from the skewer state.
- the substitution step of substituting a part of the OH group of the cyclic molecule with a group having an ionic group may be carried out by: A) the above 1) before the pseudopolyrotaxane preparation step; B) the 1) after the pseudopolyrotaxane preparation step, and Mouth taxane C) before the step; C) after the step 2) preparing the poly-mouthed taxane and before the 3) before the crosslinking step; and / or D) after the step 3) the crosslinking step. How to prepare the material.
- a method for preparing a material having a crosslinked polymouth taxane comprising the steps of: 1) mixing a cyclodextrin molecule and a linear molecule so that the linear molecule is skewered at the opening of the cyclodextrin molecule; A pseudopolyrotaxane preparation step for preparing an inclusion pseudopolyrotaxane; 2) a polypolytaxane that is prepared by blocking both ends of the pseudopolyrotaxane with a blocking group so that the cyclodextrin molecule is not released from the skewered state.
- the substitution step of substituting a part of the OH group of the cyclodextrin molecule with a group having an ionic group includes the following steps: A) the above 1) before the preparation of the pseudopolyrotaxane; B) the above 1) the pseudopolyrotaxane After the step of preparing the polybutane and after the step of preparing the polymouth taxane, and C) after the step of preparing the polymouth taxane and above 3) before the crosslinking step; and Z or D) after the above 3) crosslinking step.
- a method for preparing a material having a crosslinked polymouth taxane includes the following steps: A) the above 1) before the preparation of the pseudopolyrotaxane; B) the above
- the ionic group may be a _C ⁇ X group (X represents hydrogen (H), an alkali metal or other monovalent metal), a -SO X group (X is the same as above
- At least one selected from the group consisting of 234 groups and one HP group is preferred.
- the group having an ionic group is 10 to 90 out of all the hydroxyl groups of the all cyclic molecule. / o, preferably 20-80. / o, more preferably 30-70%, should be substituted.
- the material may absorb 100,000 g or more, preferably 2000 g or more, and more preferably 4000 g or more of solvent per lg of absolute dry state of the crosslinked polytaxane. But
- the material absorbs a solvent containing water, and changes in the pH and / or ionic strength of the solvent.
- the material absorbs at least 5 g, preferably at least 10 g, and more preferably at least 50 g of solvent per gram of absolute dryness of the crosslinked polyporous taxane at pH 2, while at pH 2 absorbs solvent per gram of absolute dryness of the crosslinked polyrotaxane at pHIO Should be absorbed at least 500 g, preferably at least 100 g, more preferably at least 2000 g.
- the solvent should be absorbed in an amount of 200 g or more, preferably 500 g or more, more preferably 1000 g or more per gram of absolute dry taxane.
- the material may absorb a solvent containing water, and the material having absorbed the solvent may change its shape and / or volume by an electric field.
- the electric field causes the cationic cyclic molecule to be localized on the negative electrode side, thereby changing the shape and Z or volume of the material, for example, bending.
- the ionic group is anionic, it is preferable that the cyclic molecule having anionic properties be localized on the positive electrode side by the electric field, thereby changing the shape and Z or volume of the material, for example, bending.
- the cyclic molecule may be a cyclodextrin. Molecule.
- the cyclic molecule is a cyclodextrin molecule, and the cyclodextrin molecule is one of cyclodextrin, ⁇ -cyclodextrin and ⁇ -cyclodextrin. It is preferably selected from the group consisting of dextrins.
- the linear molecule may be polyethylene glycol, polyisoprene, polyisobutylene, polybutadiene, polypropylene glycol, polytetrahydrofuran, polydimethylsiloxane, polyethylene, or polypropylene. It is better to be selected from the group consisting of
- the blocking group power S dinitrophenyl groups, cyclodextrins, adamantane groups, trityl groups, fluoresceins, pyrenes, substituted benzenes
- Substituents include, but are not limited to, alkyl, alkyloxy, hydroxy, halogen, cyano, sulfonyl, carboxyl, phenylamine, and the like.
- One or more substituents may be present.
- optionally substituted polynuclear aromatics substituted polynuclear aromatics
- substituents include, but are not limited to, the above.
- substituents may be present.
- steroids steroids.
- it is preferably selected from the group consisting of dinitrophenyl groups, cyclodextrins, adamantane groups, trityl groups, fluoresceins, and pyrenes, more preferably adamantane groups or trityl groups.
- the cyclic molecule is polycyclodextrin and the linear molecule is polyethylene glycol.
- ⁇ 30> in any one of the above items ⁇ 17> to ⁇ 29>, when the amount of inclusion of the cyclic molecule to the maximum when the cyclic molecule is skewered by the linear molecule is set to 1.
- the cyclic molecular force is preferably included in a skewered manner with the linear molecule in an amount of 0.001 to 0.6, preferably f to 0.01 to 0.5, more preferably 0.05 to 0.4.
- any one of the above items 17> to ⁇ 30> it is preferable that at least two molecules of the polymethyltaxane are chemically bonded by a crosslinking agent.
- the crosslinking agent may have a molecular weight of less than 2000, preferably less than 1 000, more preferably less than 600, and most preferably less than 400.
- the crosslinking agent may be, for example, cyanuric chloride, trimesyl chloride, terephthalone rechloride, epichlorohydrin, dibromobenzene, gnoletrenoleanolaldehyde, or phenylene diisocyanate. Catenate, trilein diisocyanate, divinyl sulfone, 1,1′-carbonyldiimidazole, and alkoxysilane.
- ⁇ 34> In any one of the above items 17> to ⁇ 33>, at least two molecules of the polymouth taxane may be involved in crosslinking by at least one ⁇ H group of at least one cyclic molecule of each polymouth taxane. Good to do.
- the linear molecule may have a molecular weight of not less than 10,000, preferably not less than 20,000, more preferably not less than 350,000.
- the present invention it is possible to provide a material having a crosslinked polytaxane having improved swellability.
- a material having a crosslinked polytaxane whose swelling property changes with a change in pH and / or ionic strength it is possible to provide a material having a crosslinked polytaxane whose swelling property changes with a change in pH and / or ionic strength.
- a material having a crosslinked polytaxane having responsiveness to the electric field when the electric field of the environment changes, particularly fast responsiveness, is provided. Can be provided.
- the present invention relates to a polyrotaxane in which a linear molecule is skewingly included in the opening of a cyclic molecule and blocking groups are arranged at both ends of the linear molecule so that the cyclic molecule is not eliminated.
- the ionic group of the material of the present invention is not particularly limited as long as it has ionicity.
- ionic groups include a _C ⁇ OX group (X represents hydrogen (H), an alkali metal or other monovalent metal), a -SO X group (X has the same definition as above), a -NH group , _NH X 'group ( ⁇ ' is Represents a monovalent halogen ion), -PO group, and _HP ⁇ group.
- At least one member is selected from the group consisting of these.
- the group having an ionic group accounts for 10 to 90%, preferably 2%, of the total hydroxyl groups of all the cyclic molecules.
- the material of the present invention has the following effects by having an ionic group. That is, by having an ionic group, hydration with water or hydrophilicity is increased, thereby improving solvent absorption and Z or swelling.
- the dispersibility of a cyclic molecule having an ionic group on a linear molecule changes due to a change in pH and / or ionic strength of water contained in the material or water containing the material.
- the solvent absorbability and / or swelling property changes. Specifically, when the ionic group is cationic, the solvent absorption and / or swelling property decreases as the pH increases. On the other hand, when the ionic group is anionic, as the pH increases, the solvent absorption and / or swelling properties increase.
- the electric field changes 1) the dispersibility of a cyclic molecule having an ionic group on a linear molecule.
- This change in dispersibility changes the shape and / or volume of the material.
- the ionic group is cationic
- the cationic cyclic molecule is localized on the negative electrode side.
- the ionic group has an anionic property
- the cyclic molecule having the anionic property is localized on the positive electrode side.
- Such localization changes the shape and Z or volume of the material.
- the stretchability of the crosslinked polyporous taxane is limited, so that a part of the material in which the cyclic molecule is localized contracts, while a part of the other material is Since the material is not shrunk, the material can change its shape, such as bending.
- the electric field in which the material is placed is a field in which ions are present
- ions in the material move due to the electric field, causing a local difference in ion intensity within the material.
- Materials have different swelling rates depending on the ionic strength. For example, when the ionic strength is high, the swelling rate of the material is low, while when the ionic strength is low, the swelling rate of the material is high. According to Therefore, if a local difference in ionic strength occurs in the material, the swelling ratio of the material is locally different, which causes a change in the shape of the material such as bending of the material.
- the material of the present invention should absorb 100,000 g or more, preferably 2000 g or more, and more preferably 4000 g or more of solvent per 1 g of absolute dry state of the crosslinked polytaxane.
- the material of the present invention absorbs a solvent containing water and the volume of the material changes with a change in the pH and / or ionic strength of the solvent.
- the solvent should be absorbed at least 200 g, preferably at least 500 g, more preferably at least 100 g per dry lg.
- the material of the present invention preferably absorbs a solvent containing water, and the material having absorbed the solvent preferably changes its shape and / or volume by an electric field.
- the electric field causes the cationic cyclic molecule to be localized on the negative electrode side, thereby changing the shape and / or volume of the material, for example, bending or
- the ionic group is anionic, it is preferable that the cyclic molecule having anionic properties be localized on the positive electrode side by an electric field, whereby the shape and / or volume of the material is changed, for example, the material is bent.
- the cyclic molecule is preferably a cyclodextrin molecule.
- the cyclodextrin molecule is preferably selected from the group consisting of monocyclodextrin, ⁇ -cyclodextrin and ⁇ -cyclodextrin, and is particularly preferably a cyclodextrin molecule.
- the linear molecule is selected from the group consisting of polyethylene glycol, polyisoprene, polyisobutylene, polybutadiene, polypropylene glycol, polytetrahydrofuran, polydimethylsiloxane, polyethylene, and polypropylene. Particularly, polyethylene glycol is preferred.
- the linear molecule has a molecular weight of 10,000 or more, preferably 20,000 or more, more preferably 350,000. It is good to be above.
- the capping group may be a dinitrophenyl group, a cyclodextrin, a lydamantane group, a trityl group, a fluorescein, a pyrene, a substituted benzene (the alkyl, alkyloxy, hydroxy, Examples thereof include, but are not limited to, halogen, sulphonyl sulfonyl, carboxyl, phenyl amido, etc. One or more substituents may be present.) Group (substituents include, but are not limited to, the same as those described above. One or more substituents may be present.) And steroids Is good.
- adamantane groups preferably selected from the group consisting of dinitrophenyl groups, cyclodextrins, adamantane groups, trityl groups, fluoresceins, and pyrenes, more preferably adamantan groups or trityl groups. No, it is.
- the amount of inclusion of the cyclic molecule is preferably the following amount. That is, when the amount of inclusion of the cyclic molecule to the maximum when the cyclic molecule is skewered by the linear molecule is set to 1, the cyclic molecule is 0.001 to 0.6, preferably 0.001 to 0.6. Is preferably included in a linear molecule in a skewered manner in an amount of 0.01 to 0.5, more preferably 0.05 to 0.4. When the amount of inclusion of the cyclic molecule is close to the maximum value, the movement distance of the cyclic molecule on the linear molecule tends to be limited. If the moving distance is restricted, the degree of volume change of the material tends to be restricted, which is not preferable.
- the maximum amount of inclusion of the cyclic molecule can be determined by the length of the linear molecule and the thickness of the cyclic molecule. For example, when the linear molecule is polyethylene glycol and the cyclic molecule is a cyclodextrin molecule, the maximum inclusion amount is determined experimentally (see Macromolecules 1993, 26, 5698-5703. And the entire contents of this document are incorporated herein.)
- At least two molecules of the polymouth taxane are preferably chemically bound by a crosslinking agent.
- the crosslinker should have a molecular weight of less than 2000, preferably less than 1000, more preferably less than 600, and most preferably less than 400.
- Crosslinking agents include cyanuric chloride, trimesoyl amide, terephthalate iris, and epichlorohydrid. , Dibromobenzene, glutaraldehyde, phenylene diisocyanate, trilein diisocyanate, divinyl sulfone, 1,1'-carbonyldiimidazole, and alkoxysilanes.
- At least two molecules of the polymouth taxane preferably have at least one ⁇ H group of at least one cyclic molecule of each polymouth taxane involved in crosslinking.
- the material having a crosslinked polyporous taxane of the present invention can be prepared, for example, as follows: a pseudopolyrotaxane preparation step of preparing a pseudopolyrotaxane in which linear molecules are skewered into the opening; 2) a polyrotaxane preparation step of blocking both ends of the pseudo-polyrotaxane with a blocking group to prepare a polyporous taxane so that the cyclodextrin molecule does not leave the skewer state; and 3) at least two molecules of the polyporous taxane.
- Power S can.
- substitution step of substituting a part of the ⁇ H group of the cyclic molecule with an ionic group may be carried out in any one of the above-mentioned periods A) to D) or at least two times of the periods A) to D) Can also be provided.
- the above-mentioned ones can be used as the cyclic molecule, linear molecule, blocking group and the like.
- the substitution step is preferably provided 2) after the polymouth taxane preparation step and 3) before the crosslinking step.
- the conditions used in the substitution step depend on the ionic group to be substituted, but are not particularly limited, and various reaction methods and reaction conditions can be used.
- a carboxy group which is one of the above
- oxidation of a primary hydroxyl group or ether derivatization of a primary or secondary hydroxyl group can be used.
- succinic anhydride'maleic anhydride and Z or a derivative thereof can be used.
- a solution was prepared by dissolving 0.8 g of monochloroacetic acid (or monochloroacetic acid sodium acetate) in 20 ml of DMSO. This solution was added dropwise to the polymouth taxane preparation solution, and reacted at room temperature for 24 hours. After the completion of the reaction, the reaction solution was dropped into 300 to 400 ml of vigorously stirred pure water, and the excess sodium hydroxide was immediately neutralized with 50 ml of 5N hydrochloric acid. After purifying the sample by dialysis against pure water, freeze-drying it, and carboxymethylated poly-carboxymethyl group in which part of the OH group of Hiichi CD is replaced with _CH C ⁇ H group
- Mouth taxane (PR-1) 1.19 g was obtained.
- a polymouth taxane preparation solution was obtained in the same manner as in Example 1. Separately, a solution was prepared by dissolving 1.8 g of sodium bromoethanesulfonate in 20 ml of DMSO. This solution was added dropwise to the polytaxane preparation, and reacted at room temperature for 24 hours. After completion of the reaction, the reaction solution was added dropwise to 300 to 400 ml of vigorously stirred pure water, and the excess sodium hydroxide was immediately neutralized with 50 ml of 5N hydrochloric acid.
- a polymouth taxane preparation was obtained in the same manner as in Example 1 except that the molecular weight of polyethylene glycol was changed to 500,000 (Hi-CD amount: about 1500, Hi-CD inclusion amount: about 25%).
- a solution was prepared by dissolving 2 g of sodium bromoethanesulfonate in 20 ml of DMS. The solution was added dropwise to the polytaxane preparation, and reacted at room temperature for 24 hours.
- reaction solution was dropped into 300 to 400 ml of vigorously stirred pure water, and the excess sodium hydroxide was immediately neutralized with 50 ml of 5N hydrochloric acid. After purifying the sample by dialysis against pure water, freeze-drying it and substituting a part of the 1H group of Hi-CD with _ (CH) -SONa group
- a polymouth taxane preparation solution was obtained.
- a solution was prepared by dissolving 3 g of bromoethylammonium bromide in 20 ml of DMSO. This solution was added dropwise to the above polymouth taxane preparation solution, and reacted at room temperature for 24 hours. After the completion of the reaction, the reaction solution was added dropwise to 300 to 400 ml of vigorously stirred pure water, and the excess sodium hydroxide was immediately neutralized with 5N hydrochloric acid.
- sulfoethylated polytaxane PR-2 250 mg was dissolved in 1 mL of 0.1 IN aqueous NaOH solution, and 20 / L of divinyl sulfone was further added to carry out a crosslinking reaction. After standing for 1 hour to confirm gelation, repeatedly immersed in a large amount of saline (0.01-0.1N) to remove unreacted reagents and NaOH, and to form cross-linked sulfoethylated polyporous taxane CPR-2. Obtained.
- Cross-linked sulfoethylated polymouth taxane CPR-2 was immersed in pure water to swell. The surrounding pure water was repeatedly exchanged and allowed to swell until equilibrium was reached. After sufficient swelling, water was drained on a 40-mesh net for 10 minutes, and the weight wl was measured. The obtained swelled product was freeze-dried and the weight w2 was measured.
- sulfoethylated polymouth taxane PR-2 ′ 150 mg was dissolved in 1 mL of DMSO, and 30 mg of carberdiimidazole was further added, followed by stirring well. After stirring, the mixture was defoamed under reduced pressure, and allowed to stand at 50 ° C for 1 to 3 days to perform crosslinking. After confirming gelation, the product was repeatedly immersed in a large amount of saline (0.01-0.1N) to remove unreacted reagents and DMSO, thereby obtaining a cross-linked sulfoylated polyporous taxane CPR-2 ′.
- saline 0.01-0.1N
- the crosslinked sulfoethylated polytaxane CPR-2 ′ obtained in Example 7 was repeatedly immersed in lwt%, 0.1 wt% and 0.01 wt% aqueous NaCl solution and allowed to swell until equilibrium was reached. After sufficient swelling, water was drained on a 120 ⁇ 130 mesh nylon mesh for 10 minutes, and the weight w′1 was measured. The obtained swelled product is freeze-dried or desiccator containing silica gel After drying, the dry weight w'2 was measured.
- the liquid absorption w ′ and the swelling ratio Q ′ (the weight of the liquid containing the lg polymer) were determined according to the following equations.
- c is the concentration (wt%) of the saline used in each experiment.
- Table 1 shows the obtained swelling ratio Q '.
- the ionic crosslinked polyporous taxane CPR-2 obtained in Example 6 was cut into 2.5 ⁇ 2.5 ⁇ 24 mm or 3 ⁇ 4 ⁇ 32 mm, and immersed in a 0.01 M Na CO aqueous solution. As shown in Figure 1
- Figure 2 shows the relationship between the magnitude of bending and the time when a voltage of 35 V was applied to a sample cut to 3 X 4 X 32 mm.
- the strain is defined by the displacement Y (mm), the width D (4 mm) of the gel, and the length L (32 mm) of the gel, which are defined as positive bending in the cathode direction. 6DY / L 2 (Refer to Fig. 1 (b) for bending in the cathode direction).
- the displacement Y when both ends of the gel were directed to the cathode side was defined as a positive displacement (see Y in Fig. 1 (b)). From FIG. 2, it can be seen that when a voltage is applied, the sheet first bends to the cathode side, then returns to a linear shape, and then bends to the positive electrode side.
- the sample will move in the opposite direction, faster than continuing to apply the voltage in one direction (about 30 seconds to 1 minute earlier). It has returned to a straight line.
- the value is 0.2, which indicates that it takes about 2 minutes for maximum bending.
- Example 9 A comparison between Comparative Example 1 and Example 9 shows that both of them bend in the electric field at substantially the same amount of strain (both are approximately 0.2) and at approximately the same speed.
- bending can be caused by a lower electric field (Example 9: 7 V / cm; Comparative Example 1: 30 V / cm). That is, the ionic cross-linked polyporous taxane of the present invention can cause bending more easily. This is considered to be due to the CD ring moving smoothly on the polymer chain in the ionic crosslinked polymouth taxane of Example 9.
- FIG. 1 is a conceptual view showing a shape change in an electric field of a crosslinked polytaxane of Example 9.
- FIG. 2 is a graph showing the relationship between the amount of strain of a gel and time when a voltage of 35 V is applied to a crosslinked polytaxane.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Analytical Chemistry (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Polyethers (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/579,842 US7612142B2 (en) | 2004-05-07 | 2005-05-06 | Materials having crosslinked polyrotaxane and process for producing the same |
EP05737331.8A EP1749849B1 (en) | 2004-05-07 | 2005-05-06 | Materials having crosslinked polyrotaxane and process for producing these |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004138039 | 2004-05-07 | ||
JP2004-138039 | 2004-05-07 | ||
JP2004-249828 | 2004-08-30 | ||
JP2004249828A JP5326099B2 (ja) | 2004-05-07 | 2004-08-30 | 架橋ポリロタキサンを有する材料、並びにそれらの製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005108464A1 true WO2005108464A1 (ja) | 2005-11-17 |
Family
ID=35320198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/008346 WO2005108464A1 (ja) | 2004-05-07 | 2005-05-06 | 架橋ポリロタキサンを有する材料、並びにそれらの製造方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7612142B2 (ja) |
EP (1) | EP1749849B1 (ja) |
JP (1) | JP5326099B2 (ja) |
WO (1) | WO2005108464A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006115255A1 (ja) * | 2005-04-25 | 2006-11-02 | The University Of Tokyo | ゲル状組成物及びその製造方法 |
WO2007026594A1 (ja) * | 2005-08-31 | 2007-03-08 | Nissan Motor Co., Ltd. | 親水性修飾ポリロタキサン及び架橋ポリロタキサン |
WO2007026879A1 (ja) * | 2005-09-02 | 2007-03-08 | The University Of Tokyo | ポリロタキサン含有溶液及びその使用 |
WO2007026886A1 (ja) * | 2005-09-02 | 2007-03-08 | The University Of Tokyo | ポリロタキサンのポリマーブレンド及びその使用 |
WO2008020618A1 (fr) * | 2006-08-18 | 2008-02-21 | The University Of Tokyo | Matériau contenant du polyrotaxane exerçant un haut coefficient de diffusion |
WO2009136618A1 (ja) | 2008-05-07 | 2009-11-12 | アドバンスト・ソフトマテリアルズ株式会社 | ポリロタキサン、及びポリロタキサンとポリマーとの架橋体、並びにこれらの製造方法 |
WO2009145073A1 (ja) | 2008-05-30 | 2009-12-03 | アドバンスト・ソフトマテリアルズ株式会社 | ポリロタキサン、水系ポリロタキサン分散組成物、及びポリロタキサンとポリマーとの架橋体、並びにこれらの製造方法 |
WO2010024431A1 (ja) | 2008-09-01 | 2010-03-04 | アドバンスト・ソフトマテリアルズ株式会社 | 溶媒フリーの架橋ポリロタキサンを有する材料、及びその製造方法 |
CN106554713A (zh) * | 2016-11-24 | 2017-04-05 | 上海保立佳新材料有限公司 | 一种纺织涂层胶及其制备方法 |
WO2023210427A1 (ja) | 2022-04-28 | 2023-11-02 | 古河電気工業株式会社 | 接着剤用組成物及びフィルム状接着剤、並びに、フィルム状接着剤を用いた半導体パッケージ及びその製造方法 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7883688B2 (en) * | 2005-02-03 | 2011-02-08 | Agency For Science, Technology And Research | Polycationic polyrotaxanes capable of forming complexes with nucleic acids |
CN101287775A (zh) | 2005-02-21 | 2008-10-15 | 国立大学法人东京大学 | 包含聚轮烷和聚合物的材料、及其制造方法 |
JP4521875B2 (ja) * | 2005-08-31 | 2010-08-11 | 日産自動車株式会社 | 疎水性修飾ポリロタキサン |
JP5125020B2 (ja) * | 2006-08-04 | 2013-01-23 | 日立化成工業株式会社 | 擬似架橋型環状高分子 |
JP2008208962A (ja) * | 2007-02-28 | 2008-09-11 | Furukawa Electric Co Ltd:The | 筒状管継手及び管の接続方法 |
KR20100021454A (ko) * | 2007-06-15 | 2010-02-24 | 도꾜 다이가꾸 | 주쇄 골격이 ―Si―O―로 본질적으로 이루어지는 폴리로탁산 및 그의 제조 방법, 및 상기 폴리로탁산을 가교시켜 이루어지는 가교 폴리로탁산 및 그의 제조 방법 |
JP2010086864A (ja) * | 2008-10-01 | 2010-04-15 | Japan Aviation Electronics Industry Ltd | 薄膜アクチュエータ及びこれを用いるタッチパネル |
JP5643669B2 (ja) * | 2011-01-28 | 2014-12-17 | 日本航空電子工業株式会社 | タッチパネル |
US10118996B2 (en) * | 2012-02-24 | 2018-11-06 | Purdue Research Foundation | Polyrotaxanes and uses thereof |
US20150337121A1 (en) * | 2012-06-26 | 2015-11-26 | The Johns Hopkins University | Multifunctional tunable biomaterials for tissue engineering |
US10329386B2 (en) * | 2014-07-08 | 2019-06-25 | Osaka University | Self-restoring macromolecular material and production method for same |
EP3327052B1 (en) | 2015-07-23 | 2020-03-04 | Sumitomo Chemical Company, Ltd. | Resin and surface protection plate or automotive material |
EP3687548A4 (en) | 2017-09-29 | 2021-05-26 | The Regents of the University of California | MULTI-ARMED POLYROTAXANE PLATFORM FOR PROTECTED NUCLEIC ACID DELIVERY |
US11230497B2 (en) | 2019-04-10 | 2022-01-25 | Saudi Arabian Oil Company | Cement additives |
CN114008142B (zh) * | 2019-06-19 | 2023-03-17 | 株式会社Asm | 在环状分子上具有长链烷基的聚轮烷、具有该聚轮烷的组合物和该聚轮烷的制造方法 |
US11279864B2 (en) * | 2019-10-04 | 2022-03-22 | Saudi Arabian Oil Company | Method of application of sliding-ring polymers to enhance elastic properties in oil-well cement |
US12071589B2 (en) | 2021-10-07 | 2024-08-27 | Saudi Arabian Oil Company | Water-soluble graphene oxide nanosheet assisted high temperature fracturing fluid |
US11858039B2 (en) | 2022-01-13 | 2024-01-02 | Saudi Arabian Oil Company | Direct ink printing of multi-material composite structures |
CN115537972B (zh) * | 2022-11-04 | 2023-09-19 | 南开大学 | 一种机械联锁的高性能碳化钛复合导电纤维的制备方法 |
CN117402271B (zh) * | 2023-12-14 | 2024-02-23 | 潍坊医学院 | 具有碘吸附作用聚轮烷化共价有机框架材料及其制备方法和应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5538655A (en) | 1994-06-29 | 1996-07-23 | Arthur D. Little, Inc. | Molecular complexes for use as electrolyte components |
JP2810264B2 (ja) | 1991-10-30 | 1998-10-15 | オルガノ株式会社 | ゲスト高分子がエンドキャップされたα−サイクロデキストリンの包接化合物及びゲスト高分子がエンドキャップされたサイクロデキストリンの包接化合物の製造方法 |
WO2001083566A1 (fr) * | 2000-04-28 | 2001-11-08 | Center For Advanced Science And Technology Incubation, Ltd. | Compose contenant du polyrotaxane reticule |
WO2002002159A1 (fr) * | 2000-07-03 | 2002-01-10 | Japan Tissue Engineering Co., Ltd. | Materiaux de base pour regeneration de tissus, materiaux de transplantation, et procede de fabrication |
WO2003074099A1 (fr) * | 2002-03-06 | 2003-09-12 | Japan Tissue Engineering Co.,Ltd | Materiau de base pour regeneration tissulaire, materiau de transplantation et son procede de preparation |
JP2004027183A (ja) * | 2002-02-27 | 2004-01-29 | Nobuhiko Yui | 多価結合性分子集合体、捕捉剤、薬剤基材、カルシウムキレート剤、及び、薬剤補助剤 |
US20040157989A1 (en) | 1998-06-08 | 2004-08-12 | Christoph Bruhn | Water-absorbing polymers with supramolecular hollow molecules, method for producing them and use of the same |
EP1707587A1 (en) | 2004-01-08 | 2006-10-04 | The University of Tokyo | Compound having crosslinked polyrotaxane and process for producing the same |
EP1710269A1 (en) | 2004-01-08 | 2006-10-11 | The University of Tokyo | Crosslinked polyrotaxane and process for producing the same |
EP1801199A1 (en) | 2004-09-30 | 2007-06-27 | Japan Science and Technology Agency | Cytodetaching agent and method of detaching cell sheet |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100329A (en) * | 1998-03-12 | 2000-08-08 | Virginia Tech Intellectual Properties, Inc. | Reversible, mechanically interlocked polymeric networks which self-assemble |
WO2001057140A1 (en) * | 2000-02-04 | 2001-08-09 | Massachusetts Institute Of Technology | Insulated nanoscopic pathways, compositions and devices of the same |
US6527887B1 (en) * | 2002-01-18 | 2003-03-04 | Mach I, Inc. | Polymeric cyclodextrin nitrate esters |
US20040162275A1 (en) * | 2002-02-27 | 2004-08-19 | Nobuhiko Yui | Multivalently interactive molecular assembly, capturing agent, drug carrier, calcium chelating agent, and drug enhancer |
US20030171573A1 (en) * | 2002-02-27 | 2003-09-11 | Nobuhiko Yui | Multivalently interactive molecular assembly, capturing agent, drug carrier, calcium chelating agent, and drug enhancer |
JP4467262B2 (ja) * | 2003-08-28 | 2010-05-26 | 株式会社ブリヂストン | 架橋体及びその製造方法、並びにそのリサイクル方法 |
-
2004
- 2004-08-30 JP JP2004249828A patent/JP5326099B2/ja not_active Expired - Lifetime
-
2005
- 2005-05-06 WO PCT/JP2005/008346 patent/WO2005108464A1/ja active Application Filing
- 2005-05-06 EP EP05737331.8A patent/EP1749849B1/en active Active
- 2005-05-06 US US11/579,842 patent/US7612142B2/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2810264B2 (ja) | 1991-10-30 | 1998-10-15 | オルガノ株式会社 | ゲスト高分子がエンドキャップされたα−サイクロデキストリンの包接化合物及びゲスト高分子がエンドキャップされたサイクロデキストリンの包接化合物の製造方法 |
US5538655A (en) | 1994-06-29 | 1996-07-23 | Arthur D. Little, Inc. | Molecular complexes for use as electrolyte components |
US20040157989A1 (en) | 1998-06-08 | 2004-08-12 | Christoph Bruhn | Water-absorbing polymers with supramolecular hollow molecules, method for producing them and use of the same |
WO2001083566A1 (fr) * | 2000-04-28 | 2001-11-08 | Center For Advanced Science And Technology Incubation, Ltd. | Compose contenant du polyrotaxane reticule |
EP1283218A1 (en) | 2000-04-28 | 2003-02-12 | Center for Advanced Science and Technology Incubation, Ltd. | Compound comprising crosslinked polyrotaxane |
JP3475252B2 (ja) | 2000-04-28 | 2003-12-08 | 株式会社先端科学技術インキュベーションセンター | 架橋ポリロタキサンを有する化合物 |
WO2002002159A1 (fr) * | 2000-07-03 | 2002-01-10 | Japan Tissue Engineering Co., Ltd. | Materiaux de base pour regeneration de tissus, materiaux de transplantation, et procede de fabrication |
JP2004027183A (ja) * | 2002-02-27 | 2004-01-29 | Nobuhiko Yui | 多価結合性分子集合体、捕捉剤、薬剤基材、カルシウムキレート剤、及び、薬剤補助剤 |
WO2003074099A1 (fr) * | 2002-03-06 | 2003-09-12 | Japan Tissue Engineering Co.,Ltd | Materiau de base pour regeneration tissulaire, materiau de transplantation et son procede de preparation |
EP1707587A1 (en) | 2004-01-08 | 2006-10-04 | The University of Tokyo | Compound having crosslinked polyrotaxane and process for producing the same |
EP1710269A1 (en) | 2004-01-08 | 2006-10-11 | The University of Tokyo | Crosslinked polyrotaxane and process for producing the same |
EP1801199A1 (en) | 2004-09-30 | 2007-06-27 | Japan Science and Technology Agency | Cytodetaching agent and method of detaching cell sheet |
Non-Patent Citations (10)
Title |
---|
HYUNG DAL PARK ET AL.: "Anticoagulant activity of sulfonated polyrotaxanes as blood-compatible materials", J. BIOMED. MATER. RES., vol. 60, 2002, pages 186 - 90, XP002487693 |
HYUNG DAL PARK ET AL.: "In vitro biocompatibility assessment of sulfonatedpolyrotaxane-immobilizedpolyurethane surfaces", J. BIOMED. MATER. RES., vol. 66A, 2003, pages 596 - 604 |
ICHI T ET AL: "Polyrotaxane o Kihon Kokkaku toshita 3-Jigen Soshikitai no Chosei to sono Tokusei Kaiseki.", THE JAPAN SOCIETY OF MECHANICAL ENGINEERS., 5 January 2000 (2000-01-05), pages 217 - 218, XP002994417 * |
JUNJ I WATANABE ET AL.: "Effect of acetylation of biodegradable polyrotaxanes on its supramolecular dissociation via terminal ester hydrolysis", J. BIOMAT. SCI.-POLYM. E., vol. 10, 1999, pages 1275 - 88, XP002969569 |
OKUMURA Y ET AL: "The Polyrotaxane Gel: A topological Gel by Figure-of-Eight Cross-links.", ADVANCED MATERIALS., vol. 13, no. 7, 4 April 2001 (2001-04-04), pages 485 - 487, XP001044104 * |
See also references of EP1749849A4 * |
TAKAHIRO ICHI ET AL.: "Polyrotaxane o Kihon Kokkaku toshita 3-Jigen Soshikitai no Chosei to sono Tokusei Kaiseki. /Preparation and Characterization of Three-Dimensional Architecture Based on Polyrotaxane Structure", JOURNAL OF THE JAPAN SOCIETY OF MECHANICAL ENGINEERS, 2000, pages 217 - 8 |
TOORU OOYA ET AL.: "Supramolecular Design for Multivalent Interaction: Maltose Mobility along Polyrotaxane Enhanced Binding with Concanavalin A", J. AM. CHEM. SOC., vol. 125, 2003, pages 13016 - 7, XP002523161, DOI: doi:10.1021/JA034583Z |
YASUSHI OKUMURA ET AL.: "The Polyrotaxane Gel: A Topological Gel by Figure-of-Eight Cross-links", ADV. MATER., vol. 13, 2001, pages 485 - 7, XP001044104, DOI: doi:10.1002/1521-4095(200104)13:7<485::AID-ADMA485>3.0.CO;2-T |
YOON KI JOUNG ET AL.: "Anticoagulant supramolecular-strucutred polymers: Synthesis and anti coagulant activity of taurine-conjugated carboxyethylester-polyrotaxanes", SCI. TECHNOL. ADV. MAT., vol. 6, 2005, pages 484 - 90 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006115255A1 (ja) * | 2005-04-25 | 2006-11-02 | The University Of Tokyo | ゲル状組成物及びその製造方法 |
JPWO2006115255A1 (ja) * | 2005-04-25 | 2008-12-18 | 国立大学法人 東京大学 | ゲル状組成物及びその製造方法 |
WO2007026594A1 (ja) * | 2005-08-31 | 2007-03-08 | Nissan Motor Co., Ltd. | 親水性修飾ポリロタキサン及び架橋ポリロタキサン |
WO2007026879A1 (ja) * | 2005-09-02 | 2007-03-08 | The University Of Tokyo | ポリロタキサン含有溶液及びその使用 |
WO2007026886A1 (ja) * | 2005-09-02 | 2007-03-08 | The University Of Tokyo | ポリロタキサンのポリマーブレンド及びその使用 |
WO2008020618A1 (fr) * | 2006-08-18 | 2008-02-21 | The University Of Tokyo | Matériau contenant du polyrotaxane exerçant un haut coefficient de diffusion |
WO2009136618A1 (ja) | 2008-05-07 | 2009-11-12 | アドバンスト・ソフトマテリアルズ株式会社 | ポリロタキサン、及びポリロタキサンとポリマーとの架橋体、並びにこれらの製造方法 |
US8497320B2 (en) | 2008-05-07 | 2013-07-30 | Advanced Softmaterials Inc. | Polyrotaxane, crosslinked structure comprising polyrotaxane and polymer, and processes for producing these |
JP5470246B2 (ja) * | 2008-05-07 | 2014-04-16 | アドバンスト・ソフトマテリアルズ株式会社 | ポリロタキサン、及びポリロタキサンとポリマーとの架橋体、並びにこれらの製造方法 |
WO2009145073A1 (ja) | 2008-05-30 | 2009-12-03 | アドバンスト・ソフトマテリアルズ株式会社 | ポリロタキサン、水系ポリロタキサン分散組成物、及びポリロタキサンとポリマーとの架橋体、並びにこれらの製造方法 |
JP5455898B2 (ja) * | 2008-05-30 | 2014-03-26 | アドバンスト・ソフトマテリアルズ株式会社 | ポリロタキサン、水系ポリロタキサン分散組成物、及びポリロタキサンとポリマーとの架橋体、並びにこれらの製造方法 |
WO2010024431A1 (ja) | 2008-09-01 | 2010-03-04 | アドバンスト・ソフトマテリアルズ株式会社 | 溶媒フリーの架橋ポリロタキサンを有する材料、及びその製造方法 |
CN106554713A (zh) * | 2016-11-24 | 2017-04-05 | 上海保立佳新材料有限公司 | 一种纺织涂层胶及其制备方法 |
WO2023210427A1 (ja) | 2022-04-28 | 2023-11-02 | 古河電気工業株式会社 | 接着剤用組成物及びフィルム状接着剤、並びに、フィルム状接着剤を用いた半導体パッケージ及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1749849A4 (en) | 2009-06-03 |
EP1749849B1 (en) | 2013-11-06 |
JP2005344097A (ja) | 2005-12-15 |
US7612142B2 (en) | 2009-11-03 |
EP1749849A1 (en) | 2007-02-07 |
JP5326099B2 (ja) | 2013-10-30 |
US20090011933A1 (en) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005108464A1 (ja) | 架橋ポリロタキサンを有する材料、並びにそれらの製造方法 | |
JP4521875B2 (ja) | 疎水性修飾ポリロタキサン | |
JP5388197B2 (ja) | 疎水性修飾ポリロタキサン含有溶液 | |
Prabaharan et al. | Chitosan derivatives bearing cyclodextrin cavitiesas novel adsorbent matrices | |
García-Astrain et al. | Maleimide-grafted cellulose nanocrystals as cross-linkers for bionanocomposite hydrogels | |
KR100977932B1 (ko) | 친수성 수식 폴리로탁산 및 가교 폴리로탁산 | |
KR100962771B1 (ko) | 소수성 폴리로탁산 및 가교 폴리로탁산 | |
US6828378B2 (en) | Compound comprising crosslinked polyrotaxane | |
Kim et al. | Cellulose-chitosan beads crosslinked by dialdehyde cellulose | |
Van De Manakker et al. | Cyclodextrin-based polymeric materials: synthesis, properties, and pharmaceutical/biomedical applications | |
JP4482633B2 (ja) | ポリロタキサンを有するポリマー材料、並びにその製造方法 | |
EP1900776A1 (en) | Gel composition and method for producing same | |
EP1710269A1 (en) | Crosslinked polyrotaxane and process for producing the same | |
WO2006090819A1 (ja) | ポリロタキサン及びポリマー並びにイオン性液体を有する材料、及びその製造方法 | |
Li et al. | A self-healing and multi-responsive hydrogel based on biodegradable ferrocene-modified chitosan | |
Rahmani et al. | Preparation of self-healable nanocomposite hydrogel based on Gum Arabic/gelatin and graphene oxide: Study of drug delivery behavior | |
Kumar et al. | The graft copolymerization of N-vinyl-2-pyrrolidone onto carboxymethyl cellulose and its application for controlled release of water-soluble levofloxacin | |
Aoi et al. | Synthesis and assembly of novel chitin derivatives having amphiphilic polyoxazoline block copolymer as a side chain | |
CN100547011C (zh) | 包含交联聚轮烷的材料及其制造方法 | |
JP2005320392A (ja) | 架橋ポリロタキサンを有する材料、並びにそれらの製造方法 | |
JP5051491B2 (ja) | 環状分子減量ポリロタキサンの製造方法 | |
van de Manakker et al. | Cyclodextrin-based polymeric materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580013295.5 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005737331 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005737331 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11579842 Country of ref document: US |